NEW YORK, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Wedbush Securities, one of the nation's leading financial services providers and award-winning equity research firms, will host its Wedbush PacGrow Life Sciences Management Access Conference in New York on August 12 - 13, 2014. The conference connects institutional investors with management executives from prominent public and private companies specializing in emerging pharmaceuticals, biotechnology, biopharmaceuticals, biodefense, medical device and medical diagnostics.
In addition to individual company sessions, Wedbush equity research analysts will be joined by leading experts for three panel discussions including: "Ophthalmology Treatments and Tools" hosted by Liana Moussatos, Managing Director and Tao Levy, Managing Director; "Regulatory and Reimbursement Outlook for Medical Devices and Molecular Diagnostics" hosted by Tao Levy, Managing Director; and "Gene Therapies" hosted by David Nierengarten, Managing Director.
"Investors need to know what opportunities may be available as advancements in life sciences continue to develop at a swift pace," said Mark Benson, Director of Research, Wedbush Securities. "Our conference will address these issues and provide critical insights through sector specific deep dives, moderated management presentations, one-on-one meetings and informative panels comprised of industry experts."
Companies scheduled to attend and present at the Wedbush PacGrow Life Sciences Management Access Conference include: Advanced Cell Diagnostics, Ardelyx , arGEN-X BV , Audentes Therapeutics, Auxogyn, Anacor Pharmaceuticals , Applied Genetic Technologies, Avanir Pharmaceuticals, AxoGen, BIND Therapeutics, Biodel, Blaze Bioscience, Bluebird Bio, Blueprint Medicines, Cardica, Catabasis Pharmaceuticals, Cerulean Pharma, Cepheid, Cerus, Cidara Therapeutics, Cleave Biosciences, Durata Therapeutics, Eleven Biotherapeutics, Endocyte, Epirus Biopharmaceuticals, Fibrocell Science, Foundation Medicine, GTx., Guardant Health, Hyperion Therapeutics, Intuitive Surgical, Intercept Pharmaceuticals, Iridex , Karyopharm Therapeutics, Kuros, La Jolla Pharmaceuticals, Lexicon Pharmaceuticals, MacroGenics, MEI Pharma, NGM Biopharmaceuticals, Novavax, NPS Pharmaceuticals, Ohr Pharmaceuticals, Omeros Corp., Oncolytics Biotech, Oncothyreon, OvaScience, Oxygen Biotherapeutics, Pacira Pharmaceuticals, Promedior, Prosensa Holding NV, Prothena Corporation, PTC Therapeutics, Receptos, Regulus Therapeutics, Relypsa, Sangamo BioSciences, Sequenom, STAAR Surgical, Stemline Therapeutics, Sunesis Pharmaceuticals, Synageva Biopharma, Tarsa Therapeutics, Tetraphase Pharmaceuticals, TONIX Pharmaceuticals, Ultragenyx Pharmaceutical, Vital Therapies, Xencor, Xoma and Zosano.
Wedbush Equity Research offers in-depth and differentiated research coverage across the consumer, life sciences, technology and industrial growth sectors. The team, comprised of 28 publishing analysts, generates timely, insightful analyses; and the firm's award-winning Wedbush Best Ideas List, an actively monitored compilation of stock ideas identifying outperformance trends over the forward 6 to 12 month period. Wedbush Equity Research consistently ranks among the industry's leading performance surveys including Barron's and Zacks Investment Research's "Top Stock Picking Firm," Financial Times' "Top Analysts," Institutional Investor's "Rising Stars of Wall Street Research," Wall Street Journal's "Best of the Street," and StarMine's "Analyst Awards for Excellence."
The Wedbush PacGrow Life Sciences Management Access Conference is invitation only. Please contact the Wedbush Equity Research team at (213) 688-4529 for additional information.
About Wedbush Securities
Founded in 1955, Wedbush Securities is a leading financial firm that provides brokerage, clearing, investment banking, equity research, public finance, fixed income sales and trading, and asset management to individual, institutional and issuing clients. Headquartered in Los Angeles, with over 100 registered offices, the firm focuses on relentless service, client financial safety, continuity, and advanced technology. Wedbush Securities is the largest subsidiary of holding company WEDBUSH, Inc., which also includes affiliated firms Wedbush Asset Management, Wedbush Capital Partners, Wedbush Opportunity Partners, and Lime Brokerage LLC. Follow us on Twitter @Wedbush.
Matthew Chisum Wedbush Securities 213-688-4459